Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (391-400 of 418) with videos related to

Pageof 42
Sort By:
The Journal of Allergy and Clinical Immunology|January 24, 2026
Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durabilityJames G Krueger, Ioana Cutcutache, Mark Lebwohl, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Journal of the American Academy of Dermatology|February 11, 2011
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions, Alan Menter, Neil J Korman, et al.
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Journal of the American Academy of Dermatology|July 18, 2016
The state and consequences of dermatology drug prices in the United StatesJoerg Albrecht, Mark Lebwohl, Maryam M Asgari, et al.
JAMA Dermatology|May 18, 2017
Pediatric Psoriasis Comorbidity Screening GuidelinesEmily Osier, Audrey S Wang, Megha M Tollefson, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
The Journal of Allergy and Clinical Immunology|October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studiesAna Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
Pageof 42

Showing results (391-400 of 418) with videos related to

Sort By:
Pageof 42
The Journal of Allergy and Clinical Immunology|January 24, 2026
Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durabilityJames G Krueger, Ioana Cutcutache, Mark Lebwohl, et al.
Lancet (London, England)|June 15, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsChristopher E M Griffiths, Kristian Reich, Mark Lebwohl, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Journal of the American Academy of Dermatology|February 11, 2011
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions, Alan Menter, Neil J Korman, et al.
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Journal of the American Academy of Dermatology|July 18, 2016
The state and consequences of dermatology drug prices in the United StatesJoerg Albrecht, Mark Lebwohl, Maryam M Asgari, et al.
JAMA Dermatology|May 18, 2017
Pediatric Psoriasis Comorbidity Screening GuidelinesEmily Osier, Audrey S Wang, Megha M Tollefson, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
The Journal of Allergy and Clinical Immunology|October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studiesAna Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
Pageof 42